Key facts
- RocRock Biotechnology’s last known valuation is $26.3M (Oct 2022).
- It has raised $9.1M; the latest was Early Stage VC ($7.0M) in Nov 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for RocRock Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for RocRock Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RocRock Biotechnology
Developer of genetic editing, biomaterials, and treatment for solid tumors platforms. The company is mainly focused on the development and clinical application of macrophage drugs (CAR-M) for the treatment to solid tumors, providing patients with a potential treatment to reduce the risk and better manage the tumors.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Website
- rocrockbio.com/
- Ownership
- Privately Held (backing)
RocRock Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RocRock Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RocRock Biotechnology in its N-PORT filings yet. We sweep new filings monthly.